> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Former Reviewer McGarry Joins Greenleaf Health
- URL: https://www.fdaweb.com/former-reviewer-mcgarry-joins-greenleaf-health/
- Published: 2023-11-08T12:00:00.000Z
- Updated: 2026-09-14T14:15:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155754

After an almost 18-year career at FDA, former FDA reviewer **Sarah McGarry** has joined consulting firm Greenleaf Health as senior vice president of drug and biological products. “As an infectious disease specialist, Sarah dedicated much of her career to CDER’s antivirals division, where she played a significant role in the approvals of important new antiviral products, including the first-in-class HIV treatment raltegravir (as primary reviewer), the first-in-class hepatitis C treatment sofosbuvir (as team leader), and the SARS-CoV-2 treatment Paxlovid (nirmatrelvir co-packaged with ritonavir), as well as in the emergency use authorizations for anti-SARS-CoV-2 monoclonal antibody and small molecule products,” Greenleaf says.

She also previously served as the Division of Antivirals associate director of bioinformatics from 2017-2020, “providing subject matter expertise in medical science and drug regulatory review processes and leading a multidisciplinary team within CDER responsible for modernizing the FDA’s review of marketing applications,” the group says.

McGarry has a medical degree from Georgetown University Medical School and she completed a residency in internal medicine and a fellowship in infectious diseases at Duke University.